Evidence map›Paper›PMID 18795102›Full record

ArticlePloS one2008

Fibrotic myofibroblasts manifest genome-wide derangements of translational control.

Ola Larsson, Deanna Diebold, Danhua Fan, Mark Peterson, Richard Seonghun Nho, Peter B Bitterman, Craig A Henke

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed, 1 pooled it
7.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 1 synthesis or guideline pooled it, 106 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Risk factors and management of lung cancer in idiopathic pulmonary fibrosis: A comprehensive review.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2025
    Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Ola LarssonPulmonary Division, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, United States of America. ola.larsson@mail.mcgill.ca
Deanna Diebold
Danhua Fan
Mark Peterson
Richard Seonghun Nho
Peter B Bitterman
Craig A Henke
University of Minnesota · USMcGill University · CA

Funding

Molecular Targets for Drug Discovery in IPFR01HL073719 · NHLBI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI BITTERMAN, PETER B · 2003 to 2006
$3.0M
Antifibrotic Drug Discovery in Acute Lung InjuryR01HL076779 · NHLBI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI BITTERMAN, PETER B · 2004 to 2007
$1.8M
Translational Control in IPFR01HL089249 · NHLBI · UNIVERSITY OF MINNESOTA · PI BITTERMAN, PETER B · 2008 to 2011
$1.8M
Extracellular Matrix Regulation of Fibroblast ViabilityR01HL074882 · NHLBI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI HENKE, CRAIG A · 2005 to 2008
$1.3M
NHLBI NIH HHS HL073719NHLBI NIH HHS HL 074882NHLBI NIH HHS HL076779NHLBI NIH HHS R01 HL073719NHLBI NIH HHS R01 HL074882NHLBI NIH HHS R01 HL076779NHLBI NIH HHS R01 HL089249
6 · The paper itself

Abstract

backgroundAs a group, fibroproliferative disorders of the lung, liver, kidney, heart, vasculature and integument are common, progressive and refractory to therapy. They can emerge following toxic insults, but are frequently idiopathic. Their enigmatic propensity to resist therapy and progress to organ failure has focused attention on the myofibroblast-the primary effector of the fibroproliferative response. We have recently shown that aberrant beta 1 integrin signaling in fibrotic fibroblasts results in defective PTEN function, unrestrained Akt signaling and subsequent activation of the translation initiation machinery. How this pathological integrin signaling alters the gene expression pathway has not been elucidated.

resultsUsing a systems approach to study this question in a prototype fibrotic disease, Idiopathic Pulmonary Fibrosis (IPF); here we show organized changes in the gene expression pathway of primary lung myofibroblasts that persist for up to 9 sub-cultivations in vitro. When comparing IPF and control myofibroblasts in a 3-dimensional type I collagen matrix, more genes differed at the level of ribosome recruitment than at the level of transcript abundance, indicating pathological translational control as a major characteristic of IPF myofibroblasts. To determine the effect of matrix state on translational control, myofibroblasts were permitted to contract the matrix. Ribosome recruitment in control myofibroblasts was relatively stable. In contrast, IPF cells manifested large alterations in the ribosome recruitment pattern. Pathological studies suggest an epithelial origin for IPF myofibroblasts through the epithelial to mesenchymal transition (EMT). In accord with this, we found systems-level indications for TGF-beta -driven EMT as one source of IPF myofibroblasts.

conclusionsThese findings establish the power of systems level genome-wide analysis to provide mechanistic insights into fibrotic disorders such as IPF. Our data point to derangements of translational control downstream of aberrant beta 1 integrin signaling as a fundamental component of IPF pathobiology and indicates that TGF-beta -driven EMT is one source for IPF myofibroblasts.

Indexed as

Genome, HumanProtein BiosynthesisAgedAged, 80 and overFemaleFibroblastsHumansIntegrin beta1MaleMiddle AgedModels, BiologicalPulmonary FibrosisRibosomesSignal TransductionTransforming Growth Factor betaIntegrin beta1Transforming Growth Factor beta

Identifiers

PMID18795102
PMCPMC2528966
OpenAlexW2140735560

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.